Identification of candidate serum biomarkers for small cell lung cancer by proteomics analysis

Minerva Medica

Volumn 105, Issue 2, 2014, Pages 137-147

  Shi, J ^a   Liu, J ^b   Liao, L ^c   Guo, Y ^b   Wang, H ^b   Hu, W ^d   Hu, T ^e  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI NORMAL UNIVERSITY   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Department of Medical Oncology People Hospital of Leling   (China)

^e Department of Medicine Hebei Province Cangzhou City Integration of Chinese and Western Medicine Hospital East   (China)

Author keywords

Biomarkers; Computational biology; Small cell lung carcinoma

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA1 GLYCOPROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGIOTENSINOGEN; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CERULOPLASMIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; CYTOKERATIN 1; HAPTOGLOBIN; HEME; HEMOPEXIN; HUMAN IMMUNOGLOBULIN; KININOGEN; PREALBUMIN; PREGNANCY ASSOCIATED ALPHA2 GLYCOPROTEIN; TRANSFERRIN; TUMOR MARKER;

ADULT; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG SMALL CELL CANCER; MALE; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEOMICS; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84903301807     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. http://www.china.com.cn/news/txt/2011-04/18/content-22388609.htm
2. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123(1 Suppl):259S-71S. (Pubitemid 36138804)
3. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T et al. Randomized phase III trial comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in patients with previously untreated extensive-stage disease small-cell lung Cancer. J Clin Oncol 2006;24:2038-43. (Pubitemid 46622112)
4. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer; current status. Lung Cancer 2000;28:173-85. (Pubitemid 30254226)
5. Toh CK.The changing epidemiology of lung cancer[M]. Methods in molecular biology. Totowa: Human Press; 2009. p. 397-411.
6. Slodkowska J, Zych J, Szturmowicz M, Demkow U, Rowinska-Zakrzewska E, Roszkowski-Sliz K. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study. Int J Biol Markers 2005;20:217-26. (Pubitemid 43103617)
7. Fiebiger W, Wiltschke C. Tumor markers. Acta Med Austriaca 2001;28:33-7.
8. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N et al. Predictive factors in radio-therapy for non-small celllung cancer: present status. Lung Cancer 2001;31:43-56. (Pubitemid 32012602)
9. InoueA, Narumik, Matsubara N. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. J Cancer Lett 2000;157:105-12. (Pubitemid 30421238)
10. Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H et al. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 1987;79:1629-34. (Pubitemid 17117266)
11. Ang CS, Rothacker J, Patsiouras H, Burgess AW, Nice EC. Murine fecal proteomics: A model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A 2010;1217:3330-40.
12. Rodríguez-Piñeiro AM, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal FJ, de la Cadena MP. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 2010;73:1511-1522.
13. Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF. Profiling signatures of ovarian cancer tumour suppression. using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. J Proteomics 2011;74:451-65.
14. Gromov PS.Ostergaard M.Gromova I, Celis JE. Human proteomic databases: a powerful resource for functional genomics in health and disease [J]. Prog Biophys Mol Biol 2002;80:3-22. (Pubitemid 35255010)
15. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. Ingel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Anal Biochem 1992;203:173-9.
16. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33. (Pubitemid 47087930)
17. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
18. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in priteomics[J]. BMB Rep 2008;1:615-25.
19. Chen Shijie Li Yonghe, Mo Suzhen et al. The inhibitory effect of Alpha-2-macroglobulin on tumor growth. Actaa academiae medicinae SHANG HAI 1995;2:85-8.
20. Lindner I, Hemdan NY, Buchold M, Huse K, Bigl M, Oerlecke I et al. α2-Macroglobulin Inhibits the Malignant Properties of Astrocytoma Cells by Impeding β-Catenin Signaling. Cancer Res 2010;70:277-87.
21. Lam KY, Leung PS. Regulation and expression of a rennin-angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol 2002;146:567-72. (Pubitemid 34436471)
22. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001;158:1633-7. (Pubitemid 32422928)
23. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type 1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001;116:247-54. (Pubitemid 32930137)
24. Chowa L, Rezmanna L, Catt KJ, Louis WJ, Frauman AG, Nahmias C et al. Role of the renin-angiotensin system in prostate cancer. Molecular and Cellular Endocrinology 2009;302:219-29.
25. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R et al. Potential role of rennin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecologic Oncology 2008;109:418-25.
26. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: Association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Letters 2009;283:222-9.
27. Friedrichs WE, Navarijo AL, Bowman BH. Expression and inflamamatory regulation of haptoglobin gene in adiocytes. Biochem Biophys Res Commum 2000;209:250-6.
28. McCormick DJ, Atassi MZ. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the alpha chain of human hemoglobin. J Protein Chem 1990;9:735-42.
29. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80. (Pubitemid 24049800)
30. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT et al. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 2004;24:1031-8. (Pubitemid 38624933)
31. Vostrejs M, Moran PL, Seligman PA. Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation. J Clin Invest 1988;82:331-9. (Pubitemid 18262535)
32. Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 2010;1801:806-18.
33. Sakai Y, Kim DK, Iwasa S, Liang J, Watanabe T, Onodera M et al. Bone marrow chimerism prevents atherosclerosis in arterial walls of mice deficient in apolipoprotein E. Atherosclerosis 2002;161:27-34. (Pubitemid 34214818)
34. Katan MB. Apolipoprotein E isoforms, serum cholesterol and cancer. Int J Epidemiol 2004;33:9. (Pubitemid 38500145)
35. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998;97:242-4. (Pubitemid 28067308)
36. Trost Z, Marc J, Sok M, Cerne D. Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients. Arch Med Res 2008;39:663-7.
37. Petersen CM, Jensen PH, Bukh A, Sunde L, Lamm LU, Ingerslev J. Pregnancy zone protein: a re-evaluation of serum levels in healthy women and in women suffering from breast cancer or trophoblastic disease. Scand J Clin Lab Invest 1990;50:479-85.
38. Fotiou K, Vaiopoulos G, Lilakos K, Giannopoulos A, Mandalenaki K, Marinos G et al. Serum ceruloplasmin as a marker in prostate cancer. Minerva Urol Nefrol 2007;59:407-11. (Pubitemid 350247724)
39. Kobayashi S, Nouso K, Kinugasa H, Takeuchi Y, Tomoda T, Miyahara K. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. Hepatol Res 2012.